PDE5 inhibitor drugs for use in dementia

Alzheimer's disease and related dementias (ADRD) remain a major health‐care challenge with few licensed medications. Repurposing existing drugs may afford prevention and treatment. Phosphodiesterase‐5 (PDE5) is widely expressed in vascular myocytes, neurons, and glia. Potent, selective, Food an...

Descripción completa

Detalles Bibliográficos
Autores principales: Hainsworth, Atticus H., Arancio, Ottavio, Elahi, Fanny M., Isaacs, Jeremy D., Cheng, Feixiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520293/
https://www.ncbi.nlm.nih.gov/pubmed/37766832
http://dx.doi.org/10.1002/trc2.12412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520293/
https://www.ncbi.nlm.nih.gov/pubmed/37766832
http://dx.doi.org/10.1002/trc2.12412

Ejemplares similares